Send Inquiry

Request To Call Back

Nirmatrelvir Ritonavir Tablets IP

Name: Nirmatrelvir Ritonavir Tablets IP
Brand: Bharat Pharma
Price: 3000 INR
Availability: InStock

Price 3000 INR/ Pack

Get a Price/Quote

MOQ : 100 Packs

Nirmatrelvir Ritonavir Tablets IP Specification

Pacakaging (Quantity Per Box)
30 tablets (20 Nirmatrelvir & 10 Ritonavir)

Origin of Medicine
India

Salt Composition
Nirmatrelvir and Ritonavir

Indication
Treatment of COVID-19

Life Span
24 months from manufacturing date

Brand Name
Nirmatrelvir Ritonavir Tablets IP

Dosage Form
Oral tablet

Packaging Type
Blister packaging

Drug Type
Antiviral prescription drug

Ingredients
Nirmatrelvir 150 mg and Ritonavir 100 mg

Physical Form
Other

Function
Other

Recommended For
Adults with mild to moderate COVID-19 at risk of developing severe disease

Dosage
As directed by physician, typically 2 tablets of Nirmatrelvir and 1 tablet of Ritonavir together twice daily for 5 days

Dosage Guidelines
Swallow tablets whole, do not crush or split

Suitable For
Adults

Quantity
Co-packaged tablet strip

Storage Instructions
Store below 30C, protect from moisture and light

Clinical Use
Emergency use authorized for high risk COVID-19 patients

Tablet Shape
Oval

Administration Route
Oral

Contraindications
Not recommended in patients with severe renal or hepatic impairment

Manufacturing Standard
IP (Indian Pharmacopoeia)

Marketed By
Certified Indian pharmaceutical manufacturers

Colour of Tablet
Nirmatrelvir - pink, Ritonavir - white

Packing Material
Aluminum-Aluminum blister strips

Prescription Required
Yes

Interaction Warning
May interact with other medications metabolized by CYP3A

Side Effects
Possible nausea, diarrhea, altered taste

Regulatory Approval
DCGI approved

Nirmatrelvir Ritonavir Tablets IP Trade Information

Minimum Order Quantity
100 Packs

Supply Ability
5000 Packs Per Month

Delivery Time
10 Days

Main Domestic Market
All India

About Nirmatrelvir Ritonavir Tablets IP

Highlighted as a pristine antiviral solution, Nirmatrelvir Ritonavir Tablets IP combine pink Nirmatrelvir and white Ritonavir in a spectacular dual-action formula, offering emergency use for high-risk adults battling mild to moderate COVID-19. Manufactured to invincible IP (Indian Pharmacopoeia) standards and DCGI-approved, these oval tablets come co-packaged in secure aluminum-aluminum blister strips. Order today from certified Indian suppliers and find assurance in quality and efficacy. Strict prescription is required, with dosage and guidelines provided by healthcare professionals to ensure optimal outcomes.

Advanced Application, Features & Competitive Edge

Nirmatrelvir Ritonavir Tablets IP are tailored exclusively for oral administration, applying their potent antiviral action directly where needed. Noteworthy extra features include their IP manufacturing standard, distinct color coding, and sturdy blister packaging for pristine preservation. What sets them apart is their competitive advantage of rapid deployment for high-risk COVID-19 patients, DCGI regulatory approval, and strict adherence to safety protocols-making them a leading choice among global suppliers, exporters, and traders.

Swift Delivery, Secure Packaging & Port Details

Experience quick dispatch and competitive rates when you order Nirmatrelvir Ritonavir Tablets IP. Each offer includes a co-packaged strip of 30 tablets, packed in secure aluminum blister packaging to ensure integrity during transit. Delivery timelines are streamlined, with export options via major Indian FOB ports, so you receive your order promptly and in pristine condition. Trust our efficient supply process for hassle-free fulfillment from India to your location.

FAQ's of Nirmatrelvir Ritonavir Tablets IP:

Q: How should Nirmatrelvir Ritonavir Tablets IP be administered?

A: Nirmatrelvir Ritonavir Tablets IP are taken orally, with the recommended usage being two tablets of Nirmatrelvir and one tablet of Ritonavir taken together, twice daily for five days, as directed by a physician. Tablets should be swallowed whole, not crushed or split.

Q: What patients are recommended to use Nirmatrelvir Ritonavir Tablets IP?

A: These tablets are recommended for adults with mild to moderate COVID-19 who are at risk of developing severe disease. They are not advised for individuals with severe renal or hepatic impairment.

Q: When is a prescription required for ordering these tablets?

A: A prescription is mandatory for purchasing Nirmatrelvir Ritonavir Tablets IP due to their clinical use and regulatory status. Please consult a healthcare professional for assessment and authorization.

Q: Where are Nirmatrelvir Ritonavir Tablets IP manufactured and marketed?

A: These tablets are manufactured and marketed by certified pharmaceutical companies in India, adhering to Indian Pharmacopoeia standards and DCGI regulations.

Q: What competitive advantages do Nirmatrelvir Ritonavir Tablets IP offer?

A: Their advantages include emergency use authorization, invincible IP standard manufacturing, reliable DCGI approval, robust packaging, and prompt availability for high-risk COVID-19 patients, making them a preferred choice for exporters and healthcare providers globally.

Q: How are the tablets packaged to ensure safety and efficacy?

A: Each co-packaged strip contains both Nirmatrelvir and Ritonavir tablets, sealed in aluminum-aluminum blister strips to preserve their pristine quality, protected from moisture and light, with a lifespan of 24 months.

Tell us about your requirement